文献速递淋巴瘤造血干细胞移植与细胞治疗

CD19 CAR-T细胞治疗中枢神经系统淋巴瘤的结局:一项多中心经验带来的启示

Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.
PubMed 文献 · Br J Haematol · 2025-07-01

这项多中心回顾性研究纳入54例在四家国际机构接受商业或床旁制备CD19 CAR-T细胞治疗的成人复发/难治性中枢神经系统淋巴瘤患者。CAR-T输注后第100天,65%的患者在全身和中枢神经系统两个部位均达到完全缓解作为最佳疗效。中位无进展生存期为7.5个月,1年无进展生存率为35%;中位总生存期为19个月,1年总生存率为63%。多因素分析显示CAR-T产品与无进展生存期(p=0.009)和总生存期(p=0.013)显著相关。

要点

  • 54例复发/难治性中枢神经系统淋巴瘤患者接受CD19 CAR-T治疗,第100天完全缓解率为65%。
  • 中位无进展生存期7.5个月,1年无进展生存率35%;中位总生存期19个月,1年总生存率63%。
  • ≥3级细胞因子释放综合征发生率为11%,≥3级免疫效应细胞相关神经毒性综合征为28%。

核心结论

  • 本研究支持抗CD19 CAR-T细胞治疗在中枢神经系统淋巴瘤中的可行性和安全性,且所输注的具体CAR-T产品是影响结局的因素。

研究设计与样本

  • 多中心回顾性研究,纳入54例在四家国际机构接受商业产品(axi-cel、tisa-cel、liso-cel)或床旁制备CD19 CAR-T细胞产品治疗的成人复发/难治性中枢神经系统淋巴瘤患者。

主要发现

  • CAR-T输注后第100天,65%的患者在全身和中枢神经系统两个部位均达到完全缓解作为最佳疗效。
  • 中位无进展生存期为7.5个月,1年无进展生存率为35%;中位总生存期为19个月,1年总生存率为63%。
  • 多因素分析中,CAR-T产品与无进展生存期显著相关(p=0.009),与总生存期显著相关(p=0.013)。
  • 接受tisa-cel的患者结局差于接受axi-cel的患者,接受liso-cel或床旁制备CAR-T产品的患者结局好于接受axi-cel的患者。
  • ≥3级细胞因子释放综合征发生于11%的患者,≥3级免疫效应细胞相关神经毒性综合征发生于28%的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy has reshaped the treatment paradigm for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, its role in central nervous system lymphoma (CNSL) remains uncertain. We conducted a multicentre, retrospective study on 54 adult R/R CNSL patients treated at four international institutions with commercial (axi-cel, tisa-cel, liso-cel) or a point of care (POC) CD19-CAR T-cell products. At day 100 post CAR-T infusion, 65% of patients attained a complete response as their best response in both systemic and central nervous system compartments. The median progression-free survival (PFS) was 7.5 months, with a 1-year PFS of 35%. The median overall survival (OS) was 19 months, with a 1-year OS of 63%. In multivariable analyses, CAR-T product was significantly associated with PFS (p = 0.009) and OS (p = 0.013), with patients receiving tisa-cel exhibiting poorer outcomes than axi-cel and patients receiving liso-cel or POC CAR-T product demonstrating better outcomes than axi-cel. Toxicity profiles were consistent with pivotal trials in R/R DLBCL. Grade ≥3 cytokine release syndrome occurred in 11% of patients, while grade ≥3 immune-effector cell-associated neurotoxicity syndrome was observed in 28%. Our study supports the feasibility and safety of anti-CD19 CAR-T therapy in CNSL. The specific CAR-T product infused emerged as a factor influencing outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cassanello G, Luttwak E, Brown S, et al. Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience. Br J Haematol. 2025. PMID: 40589238. doi:10.1111/bjh.20234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。